2023
Retrospective cohort study of CDK4/6-inhibitor-induced alopecia in patients with breast cancer.
Minta A, Rose L, Park C, Trovato S, Lustberg M, Sudheendra P, Cherian M, Gatti-Mays M, Stover D, Wesolowski R, Sardesai S, Ramaswamy B, Williams N, Dulmage B. Retrospective cohort study of CDK4/6-inhibitor-induced alopecia in patients with breast cancer. Journal Of Clinical Oncology 2023, 41: e13083-e13083. DOI: 10.1200/jco.2023.41.16_suppl.e13083.Peer-Reviewed Original ResearchBreast cancerEIA patientsDermatology referralsOnset of alopeciaRetrospective cohort studyMetastatic breast cancerRisk of alopeciaCyclin-dependent kinase 4Endocrine monotherapyOral minoxidilEndocrine therapyClinical improvementCohort studyRetrospective cohortFemale patientsTherapeutic optionsCombination therapyGrade severityTherapeutic responseFavorable outcomeAndrogenetic alopeciaDean scaleCDK4/6iPatientsSignificant improvement
2016
TRPV2 is a novel biomarker and therapeutic target in triple negative breast cancer
Elbaz M, Ahirwar D, Xiaoli Z, Zhou X, Lustberg M, Nasser M, Shilo K, Ganju R. TRPV2 is a novel biomarker and therapeutic target in triple negative breast cancer. Oncotarget 2016, 9: 33459-33470. PMID: 30323891, PMCID: PMC6173360, DOI: 10.18632/oncotarget.9663.Peer-Reviewed Original ResearchTriple-negative breast cancerTransient receptor potential vanilloid type-2Negative breast cancerTNBC patientsTRPV2 expressionBreast cancerHigher recurrence-free survivalRecurrence-free survivalLimited therapeutic optionsGood prognostic markerEfficacy of chemotherapyNovel therapeutic strategiesNormal breast tissueMouse model studiesFree survivalNegative patientsAggressive diseaseTherapeutic optionsCancer patientsTNBC tumorsPrognostic markerTNBC tissuesTRPV2 activationNovel biomarkersTherapeutic strategies